{
    "clinical_study": {
        "@rank": "40301", 
        "acronym": "FML", 
        "arm_group": [
            {
                "arm_group_label": "FML 0.1% eyedrops", 
                "arm_group_type": "Experimental", 
                "description": "FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days"
            }, 
            {
                "arm_group_label": "Liquifilm artificial tears eyedrops", 
                "arm_group_type": "Active Comparator", 
                "description": "Topical application 4 times a day in both eyes for 22 days"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days\n      is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates\n      the worsening  of the disease after exposure to an adverse controlled environment."
        }, 
        "brief_title": "Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes", 
                "Eye Diseases", 
                "Keratoconjunctivitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "There will be 4 visits in 3 different days:\n\n      Visit 1 (V1).  Inclusion in normalized controlled environment (NCE)\n\n      Visit 2 (V2). 21 days post-treatment. Data collected in NCE\n\n      Visit 3 (V3). 21 days post-treatment. Data collected in adverse controlled environment (ACE)\n\n      Visit 4 (V4). 22 days post-treatment. Recovery visit in ACE. Data collected in NCE"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18 years\n\n          -  Signed informed consent\n\n          -  Subjects refer worsening in their pathologies when exposed to adverse environmental\n             conditions in their daily life\n\n          -  Fluorescein corneal staining \u2265 1in Oxford Scale\n\n          -  Ocular surface disease index (OSDI) test > 12\n\n          -  Tear breakup Time (TBT) \u2264 7 seconds in both eyes\n\n          -  Schirmer test without anesthesia \u2264 10 mm in 5 minutes in both eyes\n\n          -  Any concomitant medication that may affect dry eye syndrome, ocular surface or\n             vision, must have started at least 3 months before screening visit, and there are no\n             changes in dose expected during the study duration.\n\n          -  Best corrected visual acuity at least 0.1 logMar at 6 meters with both eyes\n\n          -  Current use of ophthalmic artificial tears at study inclusion.\n\n          -  Signed informed consent\n\n          -  Signed data protection consent\n\n        Exclusion Criteria:\n\n          -  Sensitivity or known intolerance to any of the products used in the study\n\n          -  Previous severe ocular inflammation or infections in the 6 previous months to study\n             inclusion\n\n          -  Any ocular pathology other than dry eye syndrome or atopic keratoconjunctivitis\n\n          -  Any ocular surgery or trauma that may affect corneal sensitivity and / or normal tear\n             distribution (refractive or cataract surgery) in the 6 previous months or any ocular\n             or systemic surgery planned during the study duration that may affect the study as\n             assessed by principal investigator.\n\n          -  Use of contact lenses in the 3 previous months to study inclusion\n\n          -  Use of any topical medication for pathologies other than dry eye syndrome.\n\n          -  Any ocular topical treatment for dry eye syndrome with corticosteroids or non steroid\n             anti-inflammatory drugs must have stopped 1 month before study inclusion. Any\n             treatment with topical cyclosporin must have been stopped 3 months before study\n             inclusion.\n\n          -  Any uncontrolled severe systemic disease that may affect the eye (except for Sj\u00f6gren\n             Syndrome)\n\n          -  Start, discontinuation or dose change during the study of antihistaminic, cholinergic\n             agents, beta blockers, antidepressants or any other systemic medications with\n             potential effect over tear film.\n\n          -  Start of any systemic treatment that may affect dry eye syndrome, vision, ocular\n             surface or intraocular pressure during the 3 previous months to study inclusion.\n\n          -  Surgical / non surgical tear point occlusion in the 3 previous months to study\n             inclusion or prevision during study duration for this procedure.\n\n          -  Cup / disc ratio > 0.6\n\n          -  History of intraocular pressure > 22 mm Hg within 2 months previous to study\n             inclusion\n\n          -  Pregnancy or breastfeeding women\n\n          -  Inclusion in another research study in the previous 30 days to study inclusion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02051023", 
            "org_study_id": "IOBA-CERLAB-003-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "FML 0.1% eyedrops", 
                "description": "Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days", 
                "intervention_name": "FML 0.1% eyedrops", 
                "intervention_type": "Drug", 
                "other_name": "0.1% fluorometholone"
            }, 
            {
                "arm_group_label": "Liquifilm artificial tears eyedrops", 
                "description": "Liquifilm instillation 4 times a day for 22 days", 
                "intervention_name": "Liquifilm artificial tears eyedrops", 
                "intervention_type": "Drug", 
                "other_name": "Artificial tears"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Fluorometholone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "keratoconjunctivitis sicca", 
            "dry eye", 
            "dry eye syndrome", 
            "dry eye disease", 
            "steroids"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "blazquez@ioba.med.uva.es", 
                    "last_name": "Francisco Blazquez-Arauzo, MD, MsC", 
                    "phone": "(+34) 983184734"
                }, 
                "contact_backup": {
                    "email": "fjpintof@ioba.med.uva.es", 
                    "last_name": "Jose Pinto-Fraga, OD, MsC", 
                    "phone": "+34 983184750"
                }, 
                "facility": {
                    "address": {
                        "city": "Valladolid", 
                        "country": "Spain", 
                        "zip": "47011"
                    }, 
                    "name": "IOBA (Instituto de Oftalmobiolog\u00eda Aplicada), University of Valladolid"
                }, 
                "investigator": [
                    {
                        "last_name": "Margarita Calonge, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Francisco Blazquez, MD, MsC", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jose Pinto-Fraga, OD, MsC", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Alberto Lopez, OD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Maria J. Gonzalez-Garcia, OD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Amalia Enr\u00edquez de Salamanca, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Jos\u00e9 M. Herreras, MD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "blazquez@ioba.med.uva.es", 
                    "last_name": "Francisco Blazquez-Arauzo, MD, MsC", 
                    "phone": "34 983184734"
                }, 
                "contact_backup": {
                    "email": "jfpintof@ioba.med.uva.es", 
                    "last_name": "Jose Pinto-Fraga, OD, MsC", 
                    "phone": "34 983184761"
                }, 
                "facility": {
                    "address": {
                        "city": "Valladolid", 
                        "country": "Spain", 
                        "zip": "47011"
                    }, 
                    "name": "IOBA"
                }, 
                "investigator": [
                    {
                        "last_name": "Margarita Calonge-Cano, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Francisco Blazquez-Arauzo, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Alberto Lopez-Miguel, OD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Maria Jesus Gonzalez Garcia, OD, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-Masked, Vehicle-controlled Phase III Trial on the Safety/Efficacy of FML\u00ae 0.1% in the Treatment of the Inflammatory Exacerbation Provoked by Exposure to an Adverse Controlled Environment in Patients With Dry Eye Disease", 
        "overall_contact": {
            "email": "calonge@ioba.med.uva.es", 
            "last_name": "Margarita Calonge-Cano, MD, PhD", 
            "phone": "+34 983184750"
        }, 
        "overall_contact_backup": {
            "email": "blazquez@ioba.med.uva.es", 
            "last_name": "Francisco Blazquez, MD, MsC", 
            "phone": "+34 983184734"
        }, 
        "overall_official": {
            "affiliation": "Ocular surface group Director - IOBA", 
            "last_name": "Margarita Calonge-Cano, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evidence of statistically significant changes in the number of subjects with an increase \u2265 1 point in fluorescein corneal staining between pre and post adverse condition exposure in ACE (V2 vs V3) and between post adverse condition exposure in ACE and recovery visit (V3 vs V4).", 
                "measure": "Fluorescein corneal staining", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Evidence of statistically significant changes in the number of subjects with a reduction \u2265 2 points in SANDE score between pre and post adverse condition exposure in ACE (V2 vs V3) and between post adverse condition exposure and recovery visit (V3 vs V4).", 
                "measure": "Symptom Assessment in Dry Eye (SANDE) I and II questionnaire", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02051023"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evidence of statistically significant changes between the differences in tear molecule concentrations pre and post adverse condition exposure (V2 vs V3) in ACE and between post adverse condition exposure and recovery visit (V3 vs V4).", 
                "measure": "Tear inflammatory molecule levels", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Best corrected visual acuity measured with the ETDRS (Eearly Treatment for Diabetes Retinopathy Study) chart after 22 days of treatment compared to baseline", 
                "measure": "Best corrected visual acuity", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Biomicroscopy findings (general aspect of ocular surface and anterior segment, plus corneal and conjunctival staining) after 22 days of treatment compared to baseline", 
                "measure": "Biomicroscopy findings at slit lamp examination", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Adverse events that occur during the trial", 
                "measure": "Adverse events during the trial", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Conjunctival Staining (Lissamine Green; Oxford Scale) T-BUT (tear break-up time) Conjunctival hyperemia (Efron Scale) Patient satisfaction with the treatment (VAS 0-100)", 
                "measure": "Other Efficacy Measures", 
                "safety_issue": "No", 
                "time_frame": "22 days"
            }, 
            {
                "description": "Intraocular pressure levels measured with a Goldman tonometer Evaluation of optic disk/cup ratio at fundus examination", 
                "measure": "Intraocular pressure (IOP) and fundus examination", 
                "safety_issue": "Yes", 
                "time_frame": "22 days"
            }
        ], 
        "source": "Instituto Universitario de Oftalmobiolog\u00eda Aplicada", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto Universitario de Oftalmobiolog\u00eda Aplicada", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}